Fitbit (Charge / Sense / Versa) vs Evie Ring (and EvieMED) in 2026

Fitbit (Charge / Sense / Versa)

Fitbit (the Charge 6 band, plus the Sense 2 and Versa 4 watches; founded 2007 by James Park and Eric Friedman, acquired by Google in a deal that closed January 2021 for about $2.1B) is the budget-tier cleared anchor of the biometric cohort. The Charge 6, at about $160, brings cleared AFib/ECG (via electrodes on the Sense line), optical heart rate, SpO2, skin temperature, a Sleep Score and Sleep Profile, a Daily Readiness Score, and stress management, with an optional Fitbit Premium subscription (~$9.99/month).

It is a Google product line, recorded in the registry as a distinct entity from the Pixel Watch and the Google company, and its health stack shares lineage with the Pixel Watch's Fitbit/Google Health algorithms. The throughline: the strongest cardiologist-validation gradient available at a budget price point, with the AI augmenting genuine biometric sensing.

Evie Ring (and EvieMED)

Movano Health's Evie Ring is a women's-health-focused smart ring (menstrual-cycle tracking, sleep, energy, heart rate, SpO2, and mood and goal trends; general-wellness, not a diagnostic) and the lifecycle-state-paused archetype of DEPLOY's biometric ring sub-cohort. The verified-vs-claimed distinction is critical: Evie Ring sales are PAUSED, not discontinued.

Following Movano Health's Corvex reverse merger (closed March 19, 2026), an AI-infrastructure pivot, and a 1-for-10 reverse split, the company paused Evie Ring sales while a divestiture of its EvieMED clinical line is pending. EvieMED (the B2B/clinical variant) is an FDA 510(k)-cleared pulse oximeter and heart-rate device (December 2, 2024) for clinical trials, remote patient monitoring, and payors and pharma.

DEPLOY records the consumer Evie Ring at paused availability with no current retail price. Aggregators routinely flatten this as 'Movano discontinued the Evie Ring'; the accurate state is sales-paused amid a corporate pivot, with the EvieMED divestiture pending (an intention where not yet closed). Movano Health trades as NASDAQ: MOVE (CEO John Mastrototaro).